These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 15501722)

  • 1. Hans Küpper discusses science and venture capital.
    Küpper H
    Drug Discov Today; 2004 Nov; 9(21):909-12. PubMed ID: 15501722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 4. A venture capital view of challenges, opportunities, and innovation in biomedical research.
    Ratcliffe LT
    Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White biotechnology: ready to partner and invest in.
    Kircher M
    Biotechnol J; 2006; 1(7-8):787-94. PubMed ID: 16897821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 7. Navigating the clinical trial pathway: Conception, design, execution, and results dissemination.
    Sampalis JS; Watson J; Boukas S; Boukas M; Harvey N; Machado S; Bordeleau M; Rampakakis E
    Surgery; 2017 Mar; 161(3):576-583. PubMed ID: 28190508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JIM interview. Art Levinson, PhD.
    Levinson A
    J Investig Med; 1997 Jun; 45(5):230-7. PubMed ID: 9249995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustaining agbiotechnology through lean times.
    McElroy D
    Nat Biotechnol; 2003 Sep; 21(9):996-1002. PubMed ID: 12949560
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotechnology venture capital booms in Japan.
    Saegusa A
    Nat Biotechnol; 2000 Mar; 18(3):256. PubMed ID: 10700128
    [No Abstract]   [Full Text] [Related]  

  • 11. Life support for life science innovation?
    Nat Biotechnol; 2007 Feb; 25(2):144. PubMed ID: 17287731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eli Lilly enters venture capital arena.
    Fletcher L
    Nat Biotechnol; 2001 Nov; 19(11):997-8. PubMed ID: 11689830
    [No Abstract]   [Full Text] [Related]  

  • 13. 2005: biotech partners up.
    Lawrence S
    Nat Biotechnol; 2006 Feb; 24(2):126. PubMed ID: 16465145
    [No Abstract]   [Full Text] [Related]  

  • 14. Could bank loans solve Europe's biotech financing slump?
    Mitchell P
    Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276
    [No Abstract]   [Full Text] [Related]  

  • 15. 2007--a banner year for biotech.
    Lawrence S
    Nat Biotechnol; 2008 Feb; 26(2):150. PubMed ID: 18259162
    [No Abstract]   [Full Text] [Related]  

  • 16. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 17. Korean biotechs seize opportunity to list on public markets.
    Louët S
    Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042
    [No Abstract]   [Full Text] [Related]  

  • 18. Looking at US versus European exit opportunities.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech's perfect storm.
    Karberg S
    Cell; 2009 Aug; 138(3):413-5. PubMed ID: 19665960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An audience with...Joseph Bolen. Interview by Bethan Hughes.
    Bolen J
    Nat Rev Drug Discov; 2009 Aug; 8(8):608. PubMed ID: 19644470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.